FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Peakbirch Logic Inc. (the “Company” or the “Issuer”).

Trading Symbol: PKB

Number of Outstanding Listed Securities: 98,392,629

Date: March 18, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**On February 4, The Company has entered into a partnership with Halo Collective Inc., leveraging the group's formulation, manufacturing and e-commerce expertise to develop and launch a line of products combining functional, health and wellness attributes of mushrooms, without psychoactive or psychedelic properties.**

**The combined efforts are expected to deliver exceptionally high-quality, cGMP (current good manufacturing practices), functional mushroom products to individuals seeking alternative therapies and increased wellness and quality of life options.**

**The partnership group intends to leverage Halo's top-selling brand Hush to launch the innovative mushroom line known as Hushrooms. The combination of terpenes, non-psychoactive cannabinoids and mushroom extract is anticipated to deliver an uplifting yet non-psychoactive experience for consumers in easily ingested vegan capsules.**

**On February 18, the Company has put their own news release regarding the partnership with Halo.**

**Peakbirch Logic Inc. and Halo Collective Inc. have partnered to bring a new line of nutraceutical, non-psychoactive mushroom products to market. They combine the functional attributes of mushrooms and cannabinoids without the hallucinogenic properties.**

**Peakbirch is using its expertise in e-commerce and on-line presence to bring these innovative products to market. This offers the consumer a greater choice and ease of access to an innovative emerging space of wellness consumables. Product formulations will be spearheaded by manufacturing expert Nightingale Remedies, a premier and consumer-driven cannabinoid company specializing in product development and manufacturing (holding Canadian Good Manufacturing Practices licence. Halo Collective's manufacturing know-how and product design expertise will deliver an exceptionally high-quality product aimed at consumers looking for alternative therapies and greater wellness.**

**The chief executive officer of Halo Collective, Kiran Sidhu, commented: "Our industry is only in the preliminary stages of the future of wellness. Functional mushrooms will provide an initial avenue for consumers to experience the therapeutic benefits of mushrooms. We anticipate developing active psilocybin compounds via DNA synthesis of naturally occurring psylocibin using genetic clustering. We anticipate this manufacturing approach to be cost-effective and, at the same time, provide a wider spectrum with predictable modulated dosing."**

**This collaboration will provide the means to manufacture and distribute the highest-quality cGMP functional mushroom products. The initial product line, Hushrooms, will include three unique products: Rise, Mellow and Tranquil. They combine terpenes, cannabidiol, cannabigerol, cannabinol, non-psychedelic cannabinoids and mushroom extract in different combinations for each product. These unique functional benefits allow a targeted and non-psychoactive experience for consumers. The Hushrooms line of products will be available by Peakbirch's specialist mushroom sales channel, Shroommart.**

**This new partnership is at the forefront of a substantial growth potential in the mushroom market. According to Data Bridge Market Research, the functional mushroom market is expected to make substantial strides between 2021 and 2028. Data Bridge anticipates the market will grow with the compound annual growth rate of 7.22 per cent and reach $555.94-billion (U.S.) globally by 2028. Analysts have cited the increasing use of the ingredient by the nutraceutical sector to propel this growth.**

1. Provide a general overview and discussion of the activities of management.

**The Company has completed the business combination with Lifted, Greeny, Canndora, and Kootenay, in which they formed Peakbirch Logic Inc.**

**Management has been working towards expanding their brand’s web presence and overall revenue. Peakbirch will be actively seeking out new targets for acquisition in various e-commerce niches.**

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**Refer to #1**

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Refer to #1**

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**See Above.**

1. Describe the acquisition of new customers or loss of customers.

**Not applicable**

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**There were no new developments.**

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**There were no employee activities.**

1. Report on any labour disputes and resolutions of those disputes if applicable.

**Not applicable.**

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

1. Provide details of any securities issued and options or warrants granted.

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds(1)** |
| **Common shares** | **4,290,399** | **Conversion of Promissory Note** | **N/A** |
|  |  |  |  |
|  |  |  |  |

*(1) State aggregate proceeds and intended allocation of proceeds.*

1. Provide details of any loans to or by Related Persons.

**None.**

1. Provide details of any changes in directors, officers or committee members.

**N/A**

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**On Dec. 20, 2018, the United States passed the farm bill into law which included special provisions to legalize the cultivation, distribution and sale of hemp-derived products such as CBD. Since then the FDA has approved CBD products for various specific medical treatments. The market has seen exponential growth over the last two years, with growth from $620-million (U.S.) in sales in 2018 to $4.7-billion (U.S.) in sales in 2020, as reported by Brightfield Group.Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: March 18, 2021 Name of Director or Senior Officer

Marc Mulvaney

“*Marc Mulvaney*”



CEO, Director

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerPeakbirch Logic Inc.  | For Month EndFebruary 2021 | Date of ReportYY/MM/DD21/03/18 |
| Issuer Address#400 – 837 W. Hastings Street |
| City/Province/Postal CodeVancouver, BC V6C 3N6 | Issuer Fax No. | Issuer Telephone No.702-695-5582  |
| Contact NameMarc Mulvaney | Contact PositionCEO, Director | Contact Telephone No.702-695-5582  |
| Contact Email Addressinvestors@peakbirch.ca | Web Site AddressNA |